Recent Updates
Recently added Catalysts
VOR

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Key Takeaway: CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global He
Price reaction · baseline $185 (2022-02-10 close) · hit after-hours · clean, no other VOR news in the window
day 0 close
-7%
day 1 · peak
-10.9%
day 3
+1.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease

Full Press Release Details

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.
11th Annual SVB Leerink Global Healthcare Conference
Date: Friday, February 18, 2022
A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Vice President, Corporate Communications, Vor
Last updated: Feb 11, 2022